The Zacks Analyst Blog Highlights IBM, Goldman Sachs Group and Thermo Fisher Scientific

For Immediate ReleaseChicago, IL – August 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: IBM Corp. IBM, The Goldman Sachs Group, Inc. GS and Thermo Fisher Scientific Inc. TMO.Here are highlights from Monday’s Analyst Blog:Top Stock Reports for IBM, Goldman Sachs and Thermo FisherThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including IBM Corp., The Goldman Sachs Group, Inc. and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Retailers Start to Report Earnings This WeekToday's Featured Research ReportsIBM’s shares have outperformed the Zacks Computer - Integrated Systems industry over the past year (+26.8% vs. +18.8%). The company reported strong second-quarter 2025 results, with adjusted earnings and revenues beating the consensus estimate. It witnessed healthy demand trends for hybrid cloud and AI solutions, with a client-focused portfolio and broad-based growth.The acquisition of Hakkoda has strengthened its data expertise and augmented its capability to support clients’ AI transformation initiatives. IBM is collaborating with SAP to tap generative AI technology within the retail industry. The collaboration is likely to facilitate higher productivity and help accelerate business transformation in consumer-packaged goods and retail firms.However, declining net sales in the Consulting segment, owing to soft demand in some end markets, are straining margins. Macroeconomic headwinds are worrisome. IBM’s acquisition spree has also escalated integration risks.(You can read the full research report on IBM here >>>)Shares of Goldman Sachs have outperformed the Zacks Financial - Investment Bank industry over the past year (+47.3% vs. +42.8%). The company has beaten earnings estimates in the trailing four quarters. Its second-quarter 2025 results benefited from solid growth in the Global Banking & Markets division.Goldman Sachs’ refocus on the core strengths of investment banking (IB) and trading businesses through restructuring, along with acquisitions and expansion in private equity credit, is expected to boost its global presence and diversify revenues. Post-clearing the 2025 Fed stress test, it raised dividends.However, given the current geopolitical concerns, Goldman’s high dependence on overseas revenues is worrisome. Further, the company's rising expenses due to ongoing investments in technology are concerning. Yet its decent cash levels and solid credit profile will support its capital distribution plan.(You can read the full research report on Goldman Sachs here >>>)Thermo Fisher’s shares have declined -5.8% over the year-to-date period against the Zacks Medical Instruments industry’s decline of -7.3%. The company is braving the ongoing tough economic conditions by leveraging GenAI as part of the PPI Business System, resulting in strong financial performance.Thermo Fisher’s growth strategy has been bolstered by several recent product launches, including Krios 5 Cryo-TEM and Orbitrap MS systems, among others, in the second quarter. Strategic acquisitions like Solventum and Olink bode well. Thermo Fisher’s Bioproduction arm remains a key driver with new facilities and product lines.The Zacks analyst expects the company’s revenues to witness a 7.3% CAGR during fiscal 2025-2027. Robust solvency further instills optimism about the stock. However, a volatile macroeconomic environment can dent its operations. Currency woes and fierce competitive pressure add to the worry.(You can read the full research report on Thermo Fisher here >>>)Free: Instant Access to Zacks' Market-Crushing StrategiesSince 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.Get all the details here >>Zacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks